Drug – bio-affecting and body treating compositions – Live hair or scalp treating compositions
Reexamination Certificate
1997-06-05
2004-06-01
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Live hair or scalp treating compositions
C514S562000, C514S665000, C514S713000, C514S547000, C514S574000, C514S578000, C514S711000
Reexamination Certificate
active
06743419
ABSTRACT:
The invention relates to reducing hair growth in mammals.
Hair proteins include a fairly large quantity of the amino acid cysteine, which includes a thiol (—SH) group. It is the formation of disulfide bonds between cysteine residues in the hair proteins, to form cystine, that give hair its strength and character.
It is known in the art to use depilatory compositions to remove hair from, e.g., legs. Such compositions, when applied to the skin, digest the hair, in part, by breaking down the disulfide bonds in the hair. Such compositions typically include a chemical agent like calcium thioglycolate that aids the digestion process.
We have discovered that the rate of mammalian (including human) hair growth can be reduced by applying a non-depilatory composition including sulfhydryl active compounds to the skin. Sulfhydryl active compounds, as used herein, are compounds that include a free —SH group, thiols without a free —SH group, and thiols or disulfides that can be converted to a moleculer with a free —SH group in cells. Non-depilatory, as used herein, is a composition which after a single topical application does not result in hair removal and/or degradation.
Without being bound to any theory, it is believed that sulfhydryl active compounds reduce hair growth at least in part by one or more of the following mechanisms. During hair growth, cysteine is incorporated into protein chains. The —SH groups of cysteine residues in the protein chains form disulfide bonds (and cystine), binding the protein chains together as part of the normal hair growth. Sulfhydryl active compounds, applied topically, penetrate the hair follicle and interfere with hair growth by (1) reacting with free cysteine to form a mixed cysteine-sulfhydryl active compound disulfide bond, resulting in there being less cysteine available for incorporation into disulfide bonds present in hair proteins; (2) reducing the disulfide bond in cystine in the hair proteins, at the same time forming a mixed cysteine-sulfhydryl active compound disulfide bond; and (3) reducing the disulfide bond in cystine, without concomitant formation of the mixed disulfide bond.
Preferred sulfhydryl active compounds with a free —SH group include thiosalicylic acid, D-cysteine, 2-mercaptoethylamine (cysteamine), captopril, N-acetyl-L-cysteine, cysteinylglycine, 2,3-dimercapto-1-propanesulfonic acid, meso-2,3-dimercaptosuccinic acid, dimethylcysteamine, diethyldithiocarbamic acid, D-penicillamine, L-cysteine methyl ester, and L-cysteine ethyl ester.
Preferred sulfhydryl active compounds without a free —SH group include 3,3′-thiodipropionic acid, isethionic acid, 3-carboxypropyl disulfide, 3,3′-thiodipropionic acid dilauryl ester, sulfasalazine, 3-(methythio)-propylamine, 5′-deoxy-5′-methylthioadenosine, allyl sulfide, DL-&agr;-lipoic acid (reduced form), and DL-methionine-S-methyl-sulfonium chloride.
Preferred sulfhydryl active compounds that are converted to free thiols in cells include phosphocysteamine, which is dephosphorylated to cysteamine in cells; penicillamine disulfide, which is reduced to free penicillamine in cells; and S-2-aminoethyl-L-cysteine, which is hydrolyzed to cysteamine and serine (inactive) in cells.
The sulfhydryl active compounds should not be of too high a molecular weight (greater than about 1000 daltons), or contain highly charged phosphate groups, or compounds that may not adequately penetrate the skin.
The composition contains, in addition to the sulfhydryl active compound, a non-toxic dermatologically acceptable vehicle or carrier which is adapted to be spread on the skin. The concentration of the compound may be varied over a wide range up to a saturated solution, preferably from 1% to 20% by weight. The reduction of hair growth increases as the amount of sulfhydryl active compound applied increases per unit area of skin; the maximum amount that can be effectively applied is limited primarily only by the rate at which the compound penetrates the skin. Generally, the effective amounts range from 100 to 2000. micrograms or more per square centimeter of skin.
REFERENCES:
patent: 3426137 (1969-02-01), Philpitt et al.
patent: 4039669 (1977-08-01), Beyler et al.
patent: 4098802 (1978-07-01), van der Vies
patent: 4139638 (1979-02-01), Neri et al.
patent: 4161540 (1979-07-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4207315 (1980-06-01), Voorhees et al.
patent: 4228163 (1980-10-01), Bliss
patent: 4269831 (1981-05-01), Ferrari et al.
patent: 4272508 (1981-06-01), Tamm
patent: 4310523 (1982-01-01), Neumann
patent: 4344941 (1982-08-01), Wiechert et al.
patent: 4367227 (1983-01-01), Bingham
patent: 4370315 (1983-01-01), Greff et al.
patent: 4439432 (1984-03-01), Peat
patent: 4456586 (1984-06-01), Van der berghe et al.
patent: 4457925 (1984-07-01), Bittler et al.
patent: 4463016 (1984-07-01), Burgess
patent: 4525344 (1985-06-01), Tutsky
patent: 4676978 (1987-06-01), Cseh
patent: 4684635 (1987-08-01), Orenstresch et al.
patent: 4720489 (1988-01-01), Shander
patent: 4775530 (1988-10-01), Perricone
patent: 4885289 (1989-12-01), Breuer et al.
patent: 4912120 (1990-03-01), Castelhano et al.
patent: 4929630 (1990-05-01), Castelhano et al.
patent: 4935231 (1990-06-01), Pigiet
patent: 4944939 (1990-07-01), Moore
patent: 5095007 (1992-03-01), Ahluwalia
patent: 5096911 (1992-03-01), Ahluwalia et al.
patent: 5143925 (1992-09-01), Shander et al.
patent: 5362748 (1994-11-01), Schwen et al.
patent: 28 40 144 (1980-03-01), None
patent: 1458349 (1976-12-01), None
patent: 53-127432 (1978-02-01), None
patent: 58-57308 (1983-04-01), None
patent: 61-210021 (1986-09-01), None
patent: 61-289016 (1986-12-01), None
patent: 63-243017 (1988-10-01), None
patent: 9110421 (1991-07-01), None
Plewing, The Journal of Investigative Dermatology, 62:308-315 (1974).*
Chemical Abstracts 111: 120611g, 1989.*
Chemical Abstracts 118(14): 131764e, 1992.*
Gahl et al., Biochem. J., 228:545-550 (1985).
Theone et al., Brief Clin. and Lab. Observations, 96:1043-44 (1980).
Theone et al., J. Clin. Invest., 58:180 (1976).
Maiorino et al., The J. of Pharmacology and Experimental Therapeutics, 259:808 (1991).
Walshe, Clinical Studies, pp. 487-495 (Oct. 1956).
Levine, Nature, 187:940 (1960).
Schneider, NE J. Med., 313:1473 (1985).
Porter et al., Adv. Enz. Res., 27:57-59 (1988).
Pegg, Cancer Res., 48:759-74 (1988).
Luk et al., Am. J. Physiol., 254:G194-G200 (1988).
Althonen-Hongisto et al., Biochem. Biphys. Res. Comm., 144:132-137 (1987).
Casero et al., Cancer Res., 47:3964-67 (1987).
Henry et al., Br. J. Derm., 105:33-34 Supplement 20 (1981).
Luk et al., Cancer Res., 42:3070-3073 (1982).
Rupniak et al., Eur. J. Cancer Clin. Oncol., 18:1353-9 (1982).
Peterson et al., Biochem. Biophys. Acta., 657:268-276 (1981).
Kanerva et al., Arch. Toxicol. Suppl (9):455-59 (1986).
Kousa et al., Acta Dermatovener, 62:221-224 (1982).
McCullough et al., J. Invest. Dermatol., 85:518-521 (1985).
McCullough et al., J. Invest. Dermatol., 81:388-392 (1983).
Splinter et al., Eur. J. Cancer Clin. Oncol., 22:61-67 (1986).
Ebling, J. of Investigative Dermatology, 67:98-106 (1976).
Cardo et al., Hair Research 244-250 (1981).
Lucky, Arch Dermatol., 121:55-56 (1985).
Lucky et al., J. Investig. Dermatology, 86:83-86 (1986).
Goldberg, “A Method for the Colorimetric Determination of Gamma-Glutamyl Transpeptidase in Human Serum; Enzymatic Activity in Health and Disease”, 44:2:127 (1963).
Minato, Arch. of Biochemistry and Biophysics, 192:235-240 (1979).
Gardell et al., Febs Letts, 122:2:171-174 (1980).
Reed et al., Biochemistry and Biophysical Research Communications, 94:4:1273-1277 (1980).
Kim et al., J. of Dermatology 6:39-45 (1979).
Kaszynski, Brit. J. Dermatology, 109:565-569 (1983).
Richards et al., Cancer Research, 42:4143-4151 (1982).
Chase et al., Physiological Zoology, 24:1-8 (1951).
De Young et al., Cancer Research, 38:3697-3701 (1978).
Kinoshita et al., Bull. Chem. Soc. Jpn., 54:2219-2220 (1981).
Chem. Abst., 95-143848, p. 20 (1981).
Gale et al., Biochem. Pharmacology 17:2495-2498 (1968).
Jayaram et al., Biochem. Pharacol. 24:1787-1792 (1975).
Cooney et al.,
Ahluwalia Gurpreet S.
Marks-Del Grosso Diana
Shander Douglas
The Gillette Company
Wang Shengjun
LandOfFree
Method of reducing hair growth employing sulfhydryl active... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing hair growth employing sulfhydryl active..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing hair growth employing sulfhydryl active... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3321744